New Guidelines for GLP-1 Prescribing in Primary Care

New Guidelines for GLP-1 Prescribing in Primary Care: What Clinicians and Patients Need to Know

By Courtney A. Washington, DO

The rapid evolution of GLP-1 receptor agonists has fundamentally changed how primary care physicians approach obesity, diabetes, cardiovascular risk reduction, and metabolic disease.

Just a few years ago, many clinicians viewed obesity treatment as largely limited to lifestyle counseling, referral to bariatric surgery, or a handful of medications with modest efficacy.

Today, medications such as semaglutide, sold as Wegovy® and Ozempic®, and tirzepatide, sold as Zepbound® and Mounjaro®, have transformed the landscape of obesity medicine.

As clinical evidence continues to accumulate, professional organizations including the American Diabetes Association, American Association of Clinical Endocrinology, Obesity Medicine Association, and American Gastroenterological Association have updated recommendations regarding patient selection, treatment goals, cardiovascular risk reduction, and long-term management.

For primary care providers, understanding these evolving guidelines is increasingly important because obesity is no longer viewed solely as a lifestyle issue. It is recognized as a chronic disease requiring ongoing management.

The Shift From Weight Loss to Chronic Disease Management

Historically, obesity treatment focused primarily on reducing body weight.

Current guidelines increasingly emphasize treating obesity as a chronic metabolic disease that affects multiple organ systems.

Excess adiposity contributes to:

Type 2 diabetes
Hypertension
Dyslipidemia
Cardiovascular disease
Sleep apnea
Fatty liver disease
Osteoarthritis
Certain cancers

The goal is no longer simply helping patients lose weight. The goal is improving long-term health outcomes.

Updated Patient Selection Criteria

Current clinical recommendations generally support considering anti-obesity medications for adults with:

BMI ≥30 kg/m²

This applies regardless of whether obesity-related complications are already present.

BMI ≥27 kg/m²

This applies when at least one obesity-related condition is present, such as:

Hypertension
Prediabetes
Type 2 diabetes
Dyslipidemia
Obstructive sleep apnea
Cardiovascular disease

These criteria remain consistent across most major obesity treatment guidelines. However, clinicians are increasingly encouraged to assess more than BMI alone.

Looking Beyond BMI

Modern obesity medicine recognizes the limitations of BMI as a sole screening tool.

Additional factors include:

Waist Circumference

Central adiposity is strongly associated with cardiometabolic risk.

Body Composition

Assessing lean mass versus fat mass provides a more complete picture of health risk.

Metabolic Status

Important markers include A1C, fasting glucose, insulin resistance, lipid profile, and blood pressure.

Cardiovascular Risk

Patients with established cardiovascular disease may derive additional benefits from GLP-1 therapy beyond weight reduction.

Clinic Insight: BMI can help identify eligibility, but it should not be the only clinical decision point. Primary care clinicians should consider metabolic risk, cardiovascular history, body composition, functional status, and long-term disease prevention.

Which Patients May Benefit Most?

Emerging evidence suggests particularly strong consideration for patients with:

Obesity and Cardiovascular Disease

Semaglutide demonstrated reductions in major adverse cardiovascular events in the SELECT trial among patients with obesity and established cardiovascular disease.

Prediabetes

Weight reduction and improved insulin sensitivity may help delay progression to diabetes.

Type 2 Diabetes

GLP-1 receptor agonists remain an important therapeutic option because they address both glycemic control and weight management.

Metabolic Syndrome

Patients frequently experience improvements in multiple metabolic risk factors simultaneously.

Obstructive Sleep Apnea

Weight reduction may improve disease severity and overall quality of life.

Current Titration Protocols

One of the most important updates in clinical practice involves slower, more individualized dose escalation.

Early treatment experiences demonstrated that gastrointestinal side effects are often the primary reason patients discontinue therapy.

Current recommendations emphasize three principles:

Start low: Begin at the lowest available dose.
Go slow: Increase gradually according to prescribing guidelines and patient tolerance.
Individualize escalation: Not every patient requires aggressive dose advancement.

Common Semaglutide Titration Schedule

A common semaglutide titration schedule for chronic weight management is:

0.25 mg weekly for 4 weeks
0.5 mg weekly for 4 weeks
1.0 mg weekly for 4 weeks
1.7 mg weekly for 4 weeks
2.4 mg weekly maintenance

Clinicians increasingly recognize that flexibility improves adherence. Patients experiencing significant side effects may benefit from extended titration intervals.

Common Tirzepatide Titration Schedule

A common tirzepatide titration schedule is:

2.5 mg weekly for 4 weeks
5 mg weekly for 4 weeks
7.5 mg weekly
10 mg weekly
12.5 mg weekly
15 mg weekly maintenance

Treatment should be individualized rather than strictly protocol-driven.

Monitoring During Treatment

Updated recommendations emphasize ongoing monitoring rather than focusing exclusively on weight loss.

Important parameters include:

Weight and waist circumference
Blood pressure
A1C and fasting glucose
Lipid profile
Gastrointestinal side effects
Nutrition intake
Muscle mass and strength

The Importance of Muscle Preservation

One of the most important discussions occurring in obesity medicine today involves preservation of lean body mass.

Rapid weight loss can result in loss of both fat mass and lean muscle mass.

Current recommendations increasingly emphasize:

Adequate Protein Intake

Patients should prioritize protein during treatment to support lean mass preservation.

Resistance Training

Strength training remains critical for maintaining muscle and metabolic function.

Physical Activity

Regular movement helps preserve cardiometabolic health and long-term weight maintenance.

Clinic Insight: The goal is not simply a lower number on the scale. The goal is improved body composition, better labs, lower cardiovascular risk, preserved muscle, and sustainable metabolic health.

Managing Common Side Effects

Most side effects are gastrointestinal and occur during dose escalation.

Common complaints include:

Nausea
Constipation
Diarrhea
Bloating
Reflux
Early satiety

Practical strategies include smaller meals, increased hydration, slower eating, avoiding large high-fat meals, and extending titration schedules when needed.

Patient education is essential for improving adherence.

Contraindications and Precautions

GLP-1 receptor agonists are not appropriate for every patient.

Important considerations include:

Personal or family history of medullary thyroid carcinoma
Multiple Endocrine Neoplasia syndrome type 2, also known as MEN2
Severe gastrointestinal motility disorders
History of serious hypersensitivity reactions
Pregnancy or plans for pregnancy
Medication interactions and individualized risk-benefit considerations

The Future of GLP-1 Therapy in Primary Care

Perhaps the biggest shift in recent guidelines is the recognition that obesity treatment belongs in primary care.

Primary care physicians manage diabetes, hypertension, cardiovascular disease, hyperlipidemia, sleep apnea risk, and preventive health.

Obesity contributes to all of these conditions.

As newer therapies continue to emerge, including dual agonists, triple agonists, and future metabolic therapies, primary care will play an increasingly important role in identifying appropriate candidates and providing long-term management.

Key Clinical Takeaways

Current guidelines support GLP-1 therapy as part of comprehensive chronic disease management rather than a short-term weight loss strategy.

Successful treatment requires:

Appropriate patient selection
Individualized titration
Ongoing monitoring
Lifestyle intervention
Muscle preservation strategies
Long-term follow-up

Final Clinic Insight: The goal is not simply helping patients lose weight. The goal is improving metabolic health, reducing cardiovascular risk, preventing disease progression, and supporting long-term wellness. That represents the future of obesity medicine—and increasingly, the future of primary care itself.

References

American Diabetes Association. Standards of Care in Diabetes—2026. Diabetes Care. 2026.
Garvey WT, Mechanick JI, Brett EM, et al. American Association of Clinical Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. Endocrine Practice. 2022.
Wharton S, Astrup A, Endahl L, et al. Estimating Treatment Effects of Semaglutide for Obesity. Nature Medicine. 2023.
Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine. 2023;389:2221-2232.
Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022;387(3):205-216.
Obesity Medicine Association. Obesity Algorithm®. Updated 2025.
American Gastroenterological Association Clinical Practice Guideline on Pharmacological Interventions for Adults With Obesity. Gastroenterology. 2022.
Rubino DM, Greenway FL, Khalid U, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Maintenance. JAMA. 2021;325(14):1414-1425.
Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021;384(11):989-1002.
Ryan DH, Kahan S. Guideline Recommendations for Obesity Management. Medical Clinics of North America. 2023.

Disclaimer: This article is for educational purposes only and does not replace individualized medical judgment, prescribing guidance, FDA labeling, or professional clinical guidelines. Medication decisions should be made by a licensed healthcare professional based on each patient’s medical history, risk factors, current medications, and treatment goals.

```